Molecular recognition and chemical space navigation in drug discovery
dc.contributor
Universitat de Barcelona. Departament de Farmàcia i Tecnologia farmacèutica i Físicoquímica
dc.contributor.author
Piticchio, Serena
dc.date.accessioned
2022-05-11T09:10:24Z
dc.date.available
2024-05-11T22:05:17Z
dc.date.issued
2021-05-11
dc.identifier.uri
http://hdl.handle.net/10803/674218
dc.description
Programa de Doctorat en Biomedicina
en_US
dc.description.abstract
Efficient discovery of bioactive molecules is an essential goal of Computer-Aided Drug Design  (CADD). The molecules can  be used as chemical probes, to validate novel targets, or as starting points for drug discovery. This  endeavour is  particularly  challenging  in  the  case of proteins  that  are  considered undruggable  or for which  no  ligands  are  known.  These are  precisely  the  type  of proteins  that  must be  targeted in  order  to expand the “druggable genome” and  extend the range of therapeutic opportunities.
CADD  tools  available  nowadays are  numerous but  have   limitations  that  must be  overcome in  order  to improve the efficacy and  efficiency of drug discovery. Particularly because they should also be able to exploit non-standard sites, such as protein-protein interfaces, allosteric sites or cryptic pockets. They should also be adapted to  address specific  needs in  the  drug  discovery  process. Finally,  they  can  be  used to  gain  a fundamental understanding of the behaviour of molecular systems and  the rules of molecular recognition that govern  the recognition of a drug by its target. In this thesis, I have  explored each one of these aspects.
Initially, I developed  an  automatic  pipeline  that  can  be  used in Fragment-Based Drug Discovery  (FBDD) to navigate the “fragment chemical space”. Starting from a fragment hit with a known binding mode  to its target, the  platform  automatically  seeks  non-obvious analogues  (scaffold  hops)  within  large  chemical  collections, delivering fragment hits, with novel structures that would, otherwise, be missed. I validated the platform using a  fragment  hit  of the  first  bromodomain  of the  Bromodomain-containing  protein  4 (BRD4)  taken  from  the literature  as a  starting  point.  The  platform  identified  multiple  fragments  with  novel  scaffolds  and  excellent ligand efficiencies. For some, their binding modes could be corroborated experimentally.
The  optimized  fragment  identified  in  the  first  study  allowed  us to  investigate  the  unusual  behaviour of structural water  molecules in BRD4(1)  and  their role in molecular recognition. Paradoxically, a hydrophobic binding hot spot of BRD4(1) is lined with water  molecules. A series of compounds were  derived to probe  the preference  of this  site  for chemical  groups with  various  degrees of polarity.  Molecular  dynamics  (MD) and free energy calculations allowed us to rationalize the experimental results.
I have  then  used de novo design (DND) methods to further grow the most  active fragment into a very potent and efficient drug-like BRD4 ligand.
Finally,  I  have   discovered  the  first  ever  described  inhibitors  of  the  Three   Prime  Repair  Exonuclease  2 (TREX2) protein.
en_US
dc.format.extent
131 p.
en_US
dc.format.mimetype
application/pdf
dc.language.iso
eng
en_US
dc.publisher
Universitat de Barcelona
dc.rights.license
ADVERTIMENT. Tots els drets reservats. L'accés als continguts d'aquesta tesi doctoral i la seva utilització ha de respectar els drets de la persona autora. Pot ser utilitzada per a consulta o estudi personal, així com en activitats o materials d'investigació i docència en els termes establerts a l'art. 32 del Text Refós de la Llei de Propietat Intel·lectual (RDL 1/1996). Per altres utilitzacions es requereix l'autorització prèvia i expressa de la persona autora. En qualsevol cas, en la utilització dels seus continguts caldrà indicar de forma clara el nom i cognoms de la persona autora i el títol de la tesi doctoral. No s'autoritza la seva reproducció o altres formes d'explotació efectuades amb finalitats de lucre ni la seva comunicació pública des d'un lloc aliè al servei TDX. Tampoc s'autoritza la presentació del seu contingut en una finestra o marc aliè a TDX (framing). Aquesta reserva de drets afecta tant als continguts de la tesi com als seus resums i índexs.
dc.source
TDX (Tesis Doctorals en Xarxa)
dc.subject
Ciències de la salut
en_US
dc.subject
Ciencias biomédicas
en_US
dc.subject
Medical sciences
en_US
dc.subject
Disseny de medicaments
en_US
dc.subject
Diseño de medicamentos
en_US
dc.subject
Drug design
en_US
dc.subject
Reconeixement molecular
en_US
dc.subject
Reconocimiento molecular
en_US
dc.subject
Molecular recognition
en_US
dc.subject
Química farmacèutica
en_US
dc.subject
Química farmacéutica
en_US
dc.subject
Pharmaceutical chemistry
en_US
dc.subject.other
Ciències de la Salut
en_US
dc.title
Molecular recognition and chemical space navigation in drug discovery
en_US
dc.type
info:eu-repo/semantics/doctoralThesis
dc.type
info:eu-repo/semantics/publishedVersion
dc.subject.udc
577
en_US
dc.contributor.director
Barril Alonso, Xavier
dc.rights.accessLevel
info:eu-repo/semantics/openAccess


